Oxprenolol

Jump to: navigation, search
Oxprenolol
Oxprenolol.png
Clinical data
AHFS/Drugs.comMicromedex Detailed Consumer Information
Pregnancy
category
  • AU: C
Routes of
administration
oral
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability20-70%
MetabolismHepatic
Elimination half-life1-2hours
ExcretionRenal
Lactic (In lactiferous females)
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC15H23NO3
Molar mass265.348
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

WikiDoc Resources for Oxprenolol

Articles

Most recent articles on Oxprenolol

Most cited articles on Oxprenolol

Review articles on Oxprenolol

Articles on Oxprenolol in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Oxprenolol

Images of Oxprenolol

Photos of Oxprenolol

Podcasts & MP3s on Oxprenolol

Videos on Oxprenolol

Evidence Based Medicine

Cochrane Collaboration on Oxprenolol

Bandolier on Oxprenolol

TRIP on Oxprenolol

Clinical Trials

Ongoing Trials on Oxprenolol at Clinical Trials.gov

Trial results on Oxprenolol

Clinical Trials on Oxprenolol at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Oxprenolol

NICE Guidance on Oxprenolol

NHS PRODIGY Guidance

FDA on Oxprenolol

CDC on Oxprenolol

Books

Books on Oxprenolol

News

Oxprenolol in the news

Be alerted to news on Oxprenolol

News trends on Oxprenolol

Commentary

Blogs on Oxprenolol

Definitions

Definitions of Oxprenolol

Patient Resources / Community

Patient resources on Oxprenolol

Discussion groups on Oxprenolol

Patient Handouts on Oxprenolol

Directions to Hospitals Treating Oxprenolol

Risk calculators and risk factors for Oxprenolol

Healthcare Provider Resources

Symptoms of Oxprenolol

Causes & Risk Factors for Oxprenolol

Diagnostic studies for Oxprenolol

Treatment of Oxprenolol

Continuing Medical Education (CME)

CME Programs on Oxprenolol

International

Oxprenolol en Espanol

Oxprenolol en Francais

Business

Oxprenolol in the Marketplace

Patents on Oxprenolol

Experimental / Informatics

List of terms related to Oxprenolol

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Oxprenolol (Trasacor, Trasicor, Coretal, Laracor, Slow-Pren, Captol, Corbeton, Slow-Trasicor, Tevacor, Trasitensin, Trasidex) is a non-selective beta blocker with some intrinsic sympathomimetic activity. It is used for the treatment of angina pectoris, abnormal heart rhythms and high blood pressure.

Oxprenolol is a lipophilic beta blocker which passes the blood–brain barrier more easily than water soluble beta blockers. As such, it is associated with a higher incidence of CNS-related side effects than hydrophilic ligands such as atenolol, sotalol and nadolol.[1]

Oxprenolol is a potent beta blocker and should not be administered to asthmatics under any circumstances due to their low beta levels as a result of depletion due to other asthma medication, and because it can cause irreversible, often fatal, airway failure and inflammation.[2]

Stereochemistry

Oxprenolol is a chiral compound, the beta blocker is used as a racemate, e. g. a 1:1 mixture of (R)-(+)-oxprenolol and (S)-(–)-oxprenolol. Analytical methods (HPLC) for the separation and quantification of (R)-(+)-oxprenolol and (S)-(–)-oxprenolol in urine and in pharmaceutical formulations have been described in the literature.[3]

References

  1. McDevitt DG (1987). "Comparison of pharmacokinetic properties of beta-adrenoceptor blocking drugs". Eur. Heart J. 8. Suppl M: 9–14. doi:10.1093/eurheartj/8.suppl_M.9. PMID 2897304.
  2. I P Williams and F J Millard (1980). "Severe asthma after inadvertent ingestion of oxprenolol". Thorax. 35 (2): 160. doi:10.1136/thx.35.2.160. PMC 471246. PMID 7376124.
  3. Abounassif, Mohammed A.; Hefnawy, Mohammed M.; Mostafa, Gamal A. E. (2011). "Separation and quantitation of oxprenolol in urine and pharmaceutical formulations by HPLC using a Chiralpak IC and UV detection". Monatshefte für Chemie - Chemical Monthly. 143 (3): 365. doi:10.1007/s00706-011-0605-4.

Linked-in.jpg